ATE509011T1 - Pyrimidinderivate als 11beta-hsd1-inhibitoren - Google Patents

Pyrimidinderivate als 11beta-hsd1-inhibitoren

Info

Publication number
ATE509011T1
ATE509011T1 AT05755629T AT05755629T ATE509011T1 AT E509011 T1 ATE509011 T1 AT E509011T1 AT 05755629 T AT05755629 T AT 05755629T AT 05755629 T AT05755629 T AT 05755629T AT E509011 T1 ATE509011 T1 AT E509011T1
Authority
AT
Austria
Prior art keywords
11beta
pyrimidine derivatives
hsd1 inhibitors
hsd1
inhibitors
Prior art date
Application number
AT05755629T
Other languages
English (en)
Inventor
Kurt Amrein
Daniel Hunziker
Bernd Kuhn
Alexander Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE509011T1 publication Critical patent/ATE509011T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05755629T 2004-06-28 2005-06-20 Pyrimidinderivate als 11beta-hsd1-inhibitoren ATE509011T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102999 2004-06-28
PCT/EP2005/006649 WO2006000371A2 (en) 2004-06-28 2005-06-20 Pyrimidine derivatives as 11beta-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
ATE509011T1 true ATE509011T1 (de) 2011-05-15

Family

ID=35478760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05755629T ATE509011T1 (de) 2004-06-28 2005-06-20 Pyrimidinderivate als 11beta-hsd1-inhibitoren

Country Status (22)

Country Link
US (1) US7507733B2 (de)
EP (1) EP1763517B1 (de)
JP (1) JP4809339B2 (de)
CN (1) CN1972918B (de)
AR (1) AR049699A1 (de)
AT (1) ATE509011T1 (de)
AU (1) AU2005256442B2 (de)
BR (1) BRPI0512705A (de)
CA (1) CA2571361C (de)
DK (1) DK1763517T3 (de)
ES (1) ES2362884T3 (de)
IL (1) IL179914A0 (de)
MX (1) MXPA06014892A (de)
MY (1) MY143568A (de)
NO (1) NO20070445L (de)
NZ (1) NZ551859A (de)
PL (1) PL1763517T3 (de)
PT (1) PT1763517E (de)
RU (1) RU2375351C2 (de)
TW (1) TWI299040B (de)
WO (1) WO2006000371A2 (de)
ZA (1) ZA200610415B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
AR059355A1 (es) * 2006-02-07 2008-03-26 Wyeth Corp Inhibidores de 11-beta hsd1
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
EP2322505A4 (de) 2008-08-29 2011-10-19 Kowa Co 1-adamantylazetidin-2-on-derivat, herstellung davon und pharmazeutisches präparat damit
WO2010050191A1 (ja) 2008-10-29 2010-05-06 興和株式会社 1,2-ジアゼチジン-3-オン誘導体及びこれを含有する医薬
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012051139A1 (en) * 2010-10-15 2012-04-19 Amgen Inc. New uses for substituted 2-amino-thiazolones in treating alzheimer's disease
JPWO2012102366A1 (ja) * 2011-01-28 2014-06-30 日本たばこ産業株式会社 新規ピペラジン化合物の製造方法
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds
EP3235813A1 (de) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo-derivate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1229413A (de) * 1967-06-14 1971-04-21
JP2744663B2 (ja) * 1988-12-29 1998-04-28 三井化学株式会社 ピリミジン類及びその薬学的に許容される塩類
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
TW287160B (de) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2003248549B2 (en) * 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
NZ550114A (en) * 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators

Also Published As

Publication number Publication date
DK1763517T3 (da) 2011-06-06
PT1763517E (pt) 2011-07-01
US20050288308A1 (en) 2005-12-29
NO20070445L (no) 2007-01-24
AU2005256442B2 (en) 2009-02-12
CN1972918B (zh) 2010-10-13
US7507733B2 (en) 2009-03-24
HK1104553A1 (zh) 2008-01-18
CA2571361A1 (en) 2006-01-05
ES2362884T3 (es) 2011-07-14
NZ551859A (en) 2010-05-28
AU2005256442A1 (en) 2006-01-05
IL179914A0 (en) 2007-05-15
WO2006000371A3 (en) 2006-04-27
TWI299040B (en) 2008-07-21
PL1763517T3 (pl) 2011-10-31
TW200616976A (en) 2006-06-01
AR049699A1 (es) 2006-08-30
CA2571361C (en) 2011-07-26
ZA200610415B (en) 2008-06-25
MXPA06014892A (es) 2007-02-28
RU2375351C2 (ru) 2009-12-10
CN1972918A (zh) 2007-05-30
BRPI0512705A (pt) 2008-04-01
EP1763517A2 (de) 2007-03-21
JP2008504321A (ja) 2008-02-14
JP4809339B2 (ja) 2011-11-09
RU2007103303A (ru) 2008-08-10
MY143568A (en) 2011-05-31
WO2006000371A2 (en) 2006-01-05
EP1763517B1 (de) 2011-05-11

Similar Documents

Publication Publication Date Title
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
MA28824B1 (fr) Derives de pyrimidine
ATE446090T1 (de) Thiadiazolidinone als gsk3-inhibitoren
ATE494287T1 (de) Pyrazolopyrimidinderivate als inhibitoren der cyclinabhängigen kinase
ATE531705T1 (de) Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
ATE501138T1 (de) Thiophenderivate als chk-1-inhibitoren
EP1724267A4 (de) Pyrimidinderivat
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
MA28813B1 (fr) Derives de pyrimidine
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE394399T1 (de) Tetrahydropyridoindolderivate
ATE540935T1 (de) Chinazolinderivate
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
DK1761541T3 (da) Pyrrazolo-pyrimidin-derivater
ATE417830T1 (de) Sulfonylbenzimidazolderivate
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
DK1713805T3 (da) Kinaseinhibitorer
ATE430142T1 (de) Phenylpiperazin-methanon-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1763517

Country of ref document: EP